Table 6 PRO mean changes from baseline to week 52, reported by patients experiencing ≥ 1 acute exacerbation and those experiencing no acute exacerbations over the study period (analysis 2)
Mean change from baseline to week 52 | ||
|---|---|---|
No acute exacerbations | ≥ 1 acute exacerbation | |
SGRQ total score | 3.18 (n = 808) | 16.53** (n = 28) |
SGRQ symptom score | 1.93 (n = 829) | 11.09 (n = 29) |
SGRQ activity score | 4.53 (n = 821) | 12.44 (n = 28) |
SGRQ impacts score | 3.13 (n = 818) | 21.27*** (n = 28) |
UCSD-SOBQ | 6.20 (n = 735) | 22.00* (n = 23) |
CASA-Q cough symptom scorea | −0.63 (n = 835) | 0.86 (n = 29) |
CASA-Q cough impact scorea | −2.37 (n = 835) | − 8.94 (n = 29) |
EQ-5D VASa | − 3.65 (n = 821) | −7.31 (n = 29) |